Sensorineural Hearing Loss Clinical Trial
— PROACTIVE NYSOfficial title:
Prospective Observational Study of Asymptomatic cCMV Transmission to Infants for Virological Evaluation in New York State
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital CMV, from those babies with more severe findings to those with no symptoms. In particular, our study will provide new information about many facets of congenital CMV, including: - Developmental, hearing, neurologic, and vision outcomes - The spectrum and timing of symptoms - The impact congenital CMV has on the baby and its family - How many babies are infected with congenital CMV in New York State How antiviral medications and other interventions impact outcomes of children with congenital CMV Throughout the duration of the study, children will undergo routine developmental and hearing assessments, which will assist with early diagnosis of any infection complications. Any child found to have a neurodevelopmental, hearing, or vision abnormality will be referred for appropriate evaluation and treatment. Families will also be asked to complete periodic surveys about their experience with congenital CMV, both as a medical diagnosis and as it affects their day-to-day activities.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | October 1, 2026 |
Est. primary completion date | October 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Days to 1 Year |
Eligibility | Inclusion Criteria: - Neonates born in New York State during cCMV NBS Pilot Program (September 27, 2023 - October 1, 2024) - cCMV evaluation provided by a designated NYS cCMV clinical referral site - Family willing and able to complete all study procedures - Study participants meet criteria for one of the following four categories: - 1. Category 1 (Confirmed cCMV identified by NBS Program): cCMV NYS newborn screen positive AND cCMV confirmatory test positive - 2. Category 2 (Confirmed cCMV not identified by NBS Program): cCMV NYS newborn screen negative AND cCMV confirmatory test positive - 3. Category 3 (False-positive cCMV screen): cCMV NYS newborn screen positive AND negative cCMV confirmatory test - 4. Category 4 (Premature infants with confirmed CMV infection on late positive NBS): Infant born prior to 37 weeks gestation AND cCMV positive on any NYS newborn screen collected prior to 44 weeks gestational age AND Positive cCMV confirmatory test obtained within 14 days of a positive NBS Exclusion Criteria: - Neonate whose parents refuse participation in the long-term follow-up study |
Country | Name | City | State |
---|---|---|---|
United States | Stony Brook Children's Hospital | Stony Brook | New York |
Lead Sponsor | Collaborator |
---|---|
Stony Brook University | Frontier Science & Technology Research Foundation, Inc. |
United States,
Fowler KB, Boppana SB. Congenital cytomegalovirus infection. Semin Perinatol. 2018 Apr;42(3):149-154. doi: 10.1053/j.semperi.2018.02.002. Epub 2018 Mar 2. — View Citation
Pesch MH, Saunders NA, Abdelnabi S. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. J Midwifery Womens Health. 2021 May;66(3):397-402. doi: 10.1111/jmwh.13228. Epub 2021 May 24. — View Citation
Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, Daly K, Doutre S, Gibson L, Giles ML, Greenlee J, Hamilton ST, Harrison GJ, Hui L, Jones CA, Palasanthiran P, Schleiss MR, Shand AW, van Zuylen WJ. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-e188. doi: 10.1016/S1473-3099(17)30143-3. Epub 2017 Mar 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Congenital CMV infection rate | To determine the rate of confirmed congenital CMV in a statewide cohort | Study initiation to 1 year time point | |
Secondary | cCMV neonatal sensorineural hearing loss | Rate of neonatal sensorineural hearing decibel loss as determined by Auditory Brainstem Response testing | Through 4 weeks old | |
Secondary | cCMV antiviral therapy utilization | Frequency of antiviral prescriptions | 2 years | |
Secondary | cCMV acquired sensorineural hearing loss | Rate of acquired sensorineural hearing decibel loss as determined by Auditory Brainstem Response testing | 2 years | |
Secondary | cCMV neurodevelopmental outcomes | Neurodevelopmental abnormalities as measured by Bayley Scales of Infant & Toddler Development-III.
The Bayley-III includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales. Age-normalized scores are calculated for each domain, with a lower score indicating greater impairment. |
2 years | |
Secondary | cCMV-related quality of life | Quality of life score as determined by the Pediatric Quality of Life Inventory Infant Scales (PedsQL).
The PedsQL Infant Scales consist of parent-reported psychosocial health symptoms. A higher score on the PedsQL indicates more severe psychosocial health symptoms. |
2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Completed |
NCT03746613 -
Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques
|
N/A | |
Recruiting |
NCT05568329 -
Appreciation for Music Processed by Hearing Aids
|
N/A | |
Withdrawn |
NCT05061758 -
A Trial of LY3056480 in Patients With SNLH
|
Phase 2 | |
Completed |
NCT01434446 -
The Effect of Sound Stimulation on Hearing Ability
|
N/A | |
Completed |
NCT03212924 -
Listening Effort in Cochlear Implant Users
|
N/A | |
Recruiting |
NCT06053190 -
Effects of Clear Speech on Listening Effort and Memory in Sentence Processing
|
N/A | |
Completed |
NCT03718975 -
Quality Control of CE-Certified Phonak Hearing Aids - 2018_28
|
N/A | |
Completed |
NCT06025097 -
Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
|
Early Phase 1 | |
Recruiting |
NCT04102215 -
The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure
|
N/A | |
Recruiting |
NCT04108598 -
The SeaSHeL National Prospective Cohort Study
|
||
Active, not recruiting |
NCT04750642 -
Cochlear Implant With Dexamethasone Eluting Electrode Array
|
N/A | |
Completed |
NCT04120116 -
FX-322 in Adults With Stable Sensorineural Hearing Loss
|
Phase 2 | |
Recruiting |
NCT06223724 -
Status Telemetry for Cochlear Implantations
|
||
Completed |
NCT02005822 -
Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
|
Phase 3 | |
Suspended |
NCT02616172 -
Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss
|
Phase 1/Phase 2 | |
Completed |
NCT02259595 -
Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
|
Phase 1 | |
Unknown status |
NCT01902914 -
Effectiveness of P02 Digital Hearing Aids
|
Phase 1/Phase 2 | |
Completed |
NCT00589511 -
Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study
|
N/A | |
Completed |
NCT03288753 -
Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors
|
N/A |